Dyne Medical Group Secures Exclusive Distribution Rights for Robotic Suction-Irrigation System from U.S.-based VTI
“ROSI” enhances visibility, minimizes tissue damage, and boosts surgical focus during robotic procedures
CEO Seong-Hoon Lee: “Building optimized solutions — securing next-generation growth engines in laparoscopy, robotics, and AI-based surgery”
Dyne Medical Group, a global medical device company, has secured exclusive distribution rights in Korea for “ROSI,” a robotic suction-irrigation system optimized for laparoscopic surgeries. The company plans to complete regulatory approvals by 2026 and officially enter the Korean robotic surgery market.
Dyne Medical Group (CEO Sung-Hoon Lee) announced on the 22nd that it signed an exclusive supply agreement with Vascular Technology Inc. (VTI), a U.S. company specializing in precision robotic surgical solutions, for the Remotely Operated Suction Irrigation (ROSI) system in Korea.
The ROSI robotic suction-irrigation system is optimized for the robotic laparoscopic surgical environment.
ROSI is a cutting-edge device designed to allow surgeons to directly control suction and irrigation from the robotic console during laparoscopic procedures. It simultaneously improves visibility, minimizes tissue damage, and enhances surgical focus — all critical elements in robotic surgery.
In particular, ROSI enables surgeons to perform operations independently without the need for additional support staff, a functionality that has already proven effective in the robotic surgery environments of leading U.S. hospitals.
VTI, headquartered in New Hampshire, has nearly 40 years of experience in surgical medical devices, earning trust and recognition worldwide, especially for its ROSI system and surgical Doppler equipment. By leveraging VTI’s proven technology and expertise, Dyne Medical aims to quickly establish its presence in the Korean robotic surgery market.
CEO Seong-Hoon Lee stated, “This partnership is more than just a distribution deal — it’s a strategic project to introduce global innovation into domestic robotic surgery suites and marks the first step in securing Dyne’s next growth engine.”
Dyne Medical is also in active discussions with other robotic companies. The company has long considered a strategic direction in the field of surgical robotics — widely regarded as the future of surgical medical devices.
A company representative explained, “Given Dyne’s deep expertise in surgical devices and engineering capabilities, multiple robotic companies have approached us with partnership proposals. Our technical advantage lies in our ability to design ultra-miniature flexible endoscope structures and process video signals through image sensors — areas that many robotics firms struggle with.”
Additionally, most physicians currently using Dyne’s products are also engaged in robotic surgery. The topic of robotic surgical devices is frequently addressed in the medical conferences and exhibitions in which Dyne participates.
Expanding from Urology and Stone Disease to Robotic Surgery
The company has also confirmed strong marketing and sales synergy potential. Rather than diluting focus on existing business areas, expanding into surgical robotics is expected to generate even greater synergy. Accordingly, Dyne plans to extend its current portfolio — which is centered on kidney stones and urology — into the field of robotic surgery.
CEO Lee added, “Beyond supplying conventional surgical devices, we aim to build a premium solution tailored for Korea’s robotic surgery environment. This will serve as a springboard for our transition into a platform company spanning laparoscopy, robotics, and AI-based surgery.”
Meanwhile, Dyne Medical Group plans to supply ROSI devices to major university and general hospitals in Korea by 2026 and is preparing collaborative clinical programs, joint marketing initiatives, and training programs for medical professionals in partnership with VTI.
Dyne Medical Group Secures Exclusive Distribution Rights for Robotic Suction-Irrigation System from U.S.-based VTI
“ROSI” enhances visibility, minimizes tissue damage, and boosts surgical focus during robotic procedures
CEO Seong-Hoon Lee: “Building optimized solutions — securing next-generation growth engines in laparoscopy, robotics, and AI-based surgery”
Dyne Medical Group, a global medical device company, has secured exclusive distribution rights in Korea for “ROSI,” a robotic suction-irrigation system optimized for laparoscopic surgeries. The company plans to complete regulatory approvals by 2026 and officially enter the Korean robotic surgery market.
Dyne Medical Group (CEO Sung-Hoon Lee) announced on the 22nd that it signed an exclusive supply agreement with Vascular Technology Inc. (VTI), a U.S. company specializing in precision robotic surgical solutions, for the Remotely Operated Suction Irrigation (ROSI) system in Korea.
The ROSI robotic suction-irrigation system is optimized for the robotic laparoscopic surgical environment.
ROSI is a cutting-edge device designed to allow surgeons to directly control suction and irrigation from the robotic console during laparoscopic procedures. It simultaneously improves visibility, minimizes tissue damage, and enhances surgical focus — all critical elements in robotic surgery.
In particular, ROSI enables surgeons to perform operations independently without the need for additional support staff, a functionality that has already proven effective in the robotic surgery environments of leading U.S. hospitals.
VTI, headquartered in New Hampshire, has nearly 40 years of experience in surgical medical devices, earning trust and recognition worldwide, especially for its ROSI system and surgical Doppler equipment. By leveraging VTI’s proven technology and expertise, Dyne Medical aims to quickly establish its presence in the Korean robotic surgery market.
CEO Seong-Hoon Lee stated, “This partnership is more than just a distribution deal — it’s a strategic project to introduce global innovation into domestic robotic surgery suites and marks the first step in securing Dyne’s next growth engine.”
Dyne Medical is also in active discussions with other robotic companies. The company has long considered a strategic direction in the field of surgical robotics — widely regarded as the future of surgical medical devices.
A company representative explained, “Given Dyne’s deep expertise in surgical devices and engineering capabilities, multiple robotic companies have approached us with partnership proposals. Our technical advantage lies in our ability to design ultra-miniature flexible endoscope structures and process video signals through image sensors — areas that many robotics firms struggle with.”
Additionally, most physicians currently using Dyne’s products are also engaged in robotic surgery. The topic of robotic surgical devices is frequently addressed in the medical conferences and exhibitions in which Dyne participates.
Expanding from Urology and Stone Disease to Robotic Surgery
The company has also confirmed strong marketing and sales synergy potential. Rather than diluting focus on existing business areas, expanding into surgical robotics is expected to generate even greater synergy. Accordingly, Dyne plans to extend its current portfolio — which is centered on kidney stones and urology — into the field of robotic surgery.
CEO Lee added, “Beyond supplying conventional surgical devices, we aim to build a premium solution tailored for Korea’s robotic surgery environment. This will serve as a springboard for our transition into a platform company spanning laparoscopy, robotics, and AI-based surgery.”
Meanwhile, Dyne Medical Group plans to supply ROSI devices to major university and general hospitals in Korea by 2026 and is preparing collaborative clinical programs, joint marketing initiatives, and training programs for medical professionals in partnership with VTI.